Immuneel Therapeutics closes Series B of more than ₹100 crore
The cell and gene therapy company will expand manufacturing and advance its treatment pipeline.
Immuneel Therapeutics announced the close of a Series B exceeding ₹100 crore on June 8. Singularity AMC and Rainmatter joined existing backers including Kiran Mazumdar-Shaw, Eight Roads Ventures and F-Prime Capital.
The company will expand manufacturing capacity, support commercialisation of its CAR-T therapy and advance its cell and gene therapy pipeline. It also plans international expansion across Asia-Pacific and the Middle East.
Use of funds
Expand cell therapy manufacturing capacity
Develop cell and gene therapy pipeline
Support commercialisation and international expansion